Introduction
Two chimeric antigen receptor (CAR) T cell therapies (Kymriah  TM and Yescarta  TM ) were recently approved by the FDA [1, 2] . Kymriah TM (tisagenlecleucel) is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia (ALL), whereas Yescarta TM (axicabtagene ciloleucel) is for the treatment of adult patients with R/R large B cell lymphoma. They are both genetically modified autologous T cells expressing a CD19-specific CAR, lysing CD19-positive targets (normal and malignant B lineage cells). A noted difference is shown in the vectors used for Kymriah TM (lentiviral vector) and Yescarta TM (F-retroviral vector) [3] .
The overall response rate (ORR) in the short term was very high (83%), solely based on a single infusion of Kymriah TM [1] , where leukemia could not be cured by any other means, and patients went into remission within 3 months of being treated with Kymriah TM . The recipients of Yescarta TM had 72% ORR [2] . Obviously, there is no doubt about the lifesaving potential of the treatments in these hopeless cases. Numerous media reports have dramatically highlighted the lifesaving potential of Kymriah TM and Yescarta TM , and they have been coined as 'living drugs' . Indeed, this is a history-rewriting progress in cancer medicine and a quintessentially modern paradigm of clinical oncology, which not only gives hope but also directly drives innovative cancer science to patient care and leads to a paradigm shift from protocol-based treatment to real-time personalized therapy unprecedentedly. However, in the real world, even though a drug has a greater potency or a medical technology provides dramatic benefits, distinct and even serious adverse health risks can be associated either predictably or unpredictably [4] . It has been evident that many types of anticancer drugs or modalities including those modern ones with 'breakthrough designation' have induced life-threatening complications (e.g. cardiotoxicity) [5] . Kymriah TM and Yescarta TM remain therefore not only with serious patient safety events already noted in the short term but also with their long-term impacts (efficacy and safety) lacking. As all the stakeholders strive to understand the great successes, in the meantime, we should keep in mind the real-time challenges and realize gaps in the dramatic efficacy versus glaring safety concerns. Here, we analyze the crucial challenges regarding the gaps impacting quality-of-life (QOL) with the therapies, and provoke intensive debates especially regarding these potentially long-simmering problems that have not yet been fully explored. 
Challenges in synthetic immunobiology
Expansion and persistence of the CAR-modified T cells in the body are linked to many factors ( Table  1) . Any of these factors could collectively or individually influence the response in the patients treated by Kymriah TM and Yescarta TM [7, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Formulation of T cell subsets
Each T cell subset has a unique cytokine profile, functional properties and presumed roles in pathogenesis [21] and holds a specific role in protective immunity [22] . Functionally, T cells can be identified as either beneficial tumorspecific T cells or deleterious counterparts [22] . Thus, controlling the T cell subsets with favorable function compositions of a CAR T cell product is one of the most important aspects for manufacturing more-effective clinical T cell products [10, 22] . The strategy holds the potential to reduce product variability, improves the consistency of in vivo proliferation and provides reproducible potency [11, 15, 19, 22, 23] . Moreover, T cell maturation status is important as well, and it was found that less differentiated, stem-cell-like T cells possess greater therapeutic efficacy [24, 25] .
Immunosuppressive tumor microenvironment
The immune system has a double-edged role, being involved in suppressing tumor growth by destroying cancer cells and shaping the immunogenic phenotypes of tumors to promote tumor progression by escaping immunosurveillance [9, 26] . These inhibitory and immunosuppressive stimuli can impede the function of CAR T cells [27] and 'armored CARs' could improve T cell function [28] .
CD19
À variants (antigen-loss relapses) CD19 À ALL variants are being recognized with increasing frequency, rendering the CAR T cells ineffective against B cell tumors and thus representing a barrier to progress in CD19-directed immunotherapy [29, 30] . Several novel mechanisms associated with CD19 À ALL variants have been discovered [6, [31] [32] [33] (e.g. alternative mRNA splicing, CD19 gene deletion or mutation, CD19-negative clonal evolution, induction of a myeloid switch). Allogeneic stem cell transplantation (allo-SCT) and co-targeting of multiple markers on leukemic cells could be the possible solutions [6] . But tumor-specific antigens are rare, and thus multiple targeting potentially increases off-tumor, on-target toxicities [5] including neoreactivities (allo-HLA and autoreactive activity) induced by mixed T cell receptor (TCR) dimers [34] .
CAR protein and RNA downregulation
CAR expression is decreased upon repeated stimulations [24, 35, 36] or when there is accelerated differentiation and exhaustion of the T cells [24, 36] . These problems pose additional challenges of CAR in CAR T cell therapy. A possible solution for the problem is to direct a CD19-specific CAR to the TCR a constant (TRAC) locus by CRISPR/Cas9 genome editing [35] , which potentially yields some benefits (e.g. decreased T cell differentiation and exhaustion [22, 37, 38] , minimizing the risks of insertional oncogenesis and TCR-induced autoimmunity and alloreactivity [35] ).
High dose of corticosteroids
It is unclear whether tocilizumab has any beneficial effects on neurotoxicities [39] , because its size makes efficient blood-brain barrier (BBB) penetration unlikely [33, 40] . Thus, the first-line agent to treat severe neurotoxicities is often with systemic corticosteroids rather than tocilizumab [33, 39] . However, prolonged use of high-dose corticosteroids results in ablation of the CAR T cell population [20, 41] . Moreover, inappropriate use of glucocorticoids is associated with risk for early relapse of primary disease [41] .
Extramedullary disease
The central nervous system (CNS) is a well-recognized reservoir wherein leukemia can escape systemic cytotoxic therapy [42] . The CNS compartment is affected in roughly one-third of ALL relapses [43, 44] , whereas CNS involvement at relapse occurs mainly in patients who were CNSnegative at initial diagnosis [44, 45] . Intriguingly, CD19 CAR T cells have been identified in the cerebrospinal fluid (CSF) of patients after infusion [46] [47] [48] , even though many of the patients (80%) did not have a history of CNS leukemia [49] , suggesting the ability of these cells to cross the BBB [47, 50] . Thus, the therapy might be considered to replace multiple doses of either prophylactic or therapeutic, intrathecal chemotherapy and radiation in leukemia patients. Theoretically, the replacement could reduce cognitive impairment and developmental delay resulting from chemotherapy and radiation in the patient population, because ALL is most commonly diagnosed in children under 8 years of age, a crucial time in brain development [51] . However, a contradictory event in parallel consideration is neurotoxicity -one of the major complications of Kymriah TM and Yescarta TM . As a result, caution should always be taken when considering the replacement. Furthermore, detection of CD19 expression in the brain parenchyma remains controversial [25] , and thus the capacity for clearance of Extramedullary disease (EMD) by the therapy remains uncertain [22] and further research in this area is warranted. Cytokine-release syndrome and NT: neurotoxicity) remains unfeasible, because either the mechanisms of these toxicities remain poorly understood (e.g. NT) [22] or CAR T products have endogenously inherited features (e.g. CRS). To date, palliative supportive care (PSC) and immunosuppression remain the only approaches [7, 20] Cell lineage and differentiation state
Component variability of the product Impact the reproducible potency Improve production method [7, 11, 15, 20, 28, 38] Cell viability Nonviable cells Impact the efficacy and safety profile Improve production method [7, 10] Cellular impurities Non T cells (B lineage cells, blasts and others)
Impact the efficacy and safety profile Improve production method [7, 10] Excipients (DMSO, dextran 40) Anaphylaxis Impact the safety profile Improve production method [1, 7, 10] Manufacturing failures Poor starting autologous leukapheresis cells
Jeopardize disease control and survival Use universal CAR19 T cells [7, 10, 18] Specificity of the scFv domain Determinant for the CAR T cell safety profile
Off-target activity and B cell aplasia Use therapeutic immunoglobulin, antiFcmR CAR T, RNA CARs [7, 14, 20] Affinity of scFv binding CAR T cell activation and effector functions Impact the safety and activity Not restricted by MHC (applicable to any MHC haplotype) [7] Functional T cell subsets and ratios
Component variability of the product
Impact the reproducible potency Improve production method [7, 11, 20, 22] IFN-g production A prerequisite for CAR T cell activity An indicator of T cell activation In vitro data may not correlate to in vivo efficacy, technical advances [7] CAR signaling domains and spacer variants
Off-target T cell activation Impact the safety and activity (CD19-independent toxicities) Biological optimization [7, 12, 13, 16, 17, 20] Decreased CAR expression Repeated stimulations, accelerated diff/ex
Reduced efficacy TRAC-CAR to decrease differentiation of T cells, other approaches [24, 35, 36] T cell dose versus tumor burden An inverse correlation Impact the expansion and persistence Bridging therapy to reduce tumor burden before Kymriah TM [11, 28] Immunosuppressive environment Extramedullary disease (EMD) Sanctuary site relapse (e.g. CNS) Uncertain capacity for clearance of EMD Further studies for confirmation [22, 25] Lymphodepletion chemotherapy Conditioning regimen to reduce tumor burden Augment the antitumor effects Risk of cumulative toxicities [7, 11, 28] High dose of corticosteroids Impede CAR T cell function Diminished efficacy owing to immunosuppression Tocilizumab, uncertain effects for neurotoxicities [20] Abbreviations: IS, immune system; DMSO, dimethyl sulfoxide; MHC, major histocompatibility complex; IFN-g, interferon gamma; TRAC, T cell receptor a constant locus; diff, differentiation; ex, exhaustion; del, deletion; mut, mutation; scFv, Abbreviations: CRS, cytokine release syndrome; TLS, tumor lysis syndrome; DIC, disseminated intravascular coagulation; MAS, macrophage activation syndrome; GVHD, graft-versus-host disease; DAMPS, damage-associated molecular patterns; HSCT, hematopoietic stem cell transplantation; REMS, Risk Evaluation and Mitigation Strategy; ETASU, Elements to Assure Safe Use.
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Features PERSPECTIVE for treating these common complications [1, 2] , even considering the latest new guidelines [52] . Recently, a human study explored the mechanism of NT and suggested that an increased BBB permeability might explain NT [53] . The study could lead to further studies for development of novel treatment on the basis of mechanisms. B cell aplasia (acquired hypogammaglobulinemia) is an on-target off-tumor toxicity for CD19-targeted CAR [1,2] (i.e. a specific toxicity of CD19 CAR T) because CD19 is a cell-surface component of B cell lineage [3] . There are several possible solutions to potentially overcoming or minimizing B cell aplasia: (i) use of anti-FcmR CAR T [14] ; (ii) use of RNA CARs [20] ; (iii) infusion of pooled immunoglobulins [1, 2] . Beyond this, additive side-effects (secondary or tertiary toxicities) derived from combining or bridging agents should not be overlooked (e.g. tocilizumab with an FDA warning and precaution labels [54] , ibrutinib to prevent CRS after using anti-CD19 CART [55] with known cardiac concerns [5] and other serious complications [56, 57] ). Furthermore, the use of host lymphodepletion chemotherapy with immunosuppressive agents (e.g. cyclophosphamide) before a CAR T approach is a required step to augment the antitumor effects of this treatment [1, 2, 5, 7] . However, such concomitant therapies can lead to clinical cardiotoxicity [5] . Consequently, these combining or bridging agents might increase some cumulative or synergistic toxicities for the patients.
Uncertain long-term outcomes of Kymriah TM and Yescarta TM Data were fast-emerging on the early responses to Kymriah TM and Yescarta TM , thus most of the patients participating in the trials have only been followed for a relatively short period of time [1, 2] , limiting the ability to assess the risk of long-term adverse events and rule them out. As a result, long-term sequelae and late toxic effects of Kymriah TM and Yescarta TM remain unknown although some are theoretically predictable (Table 2) . Theoretically, the aftermath of the immuno-bombing in the human body can be just as deadly and far-reaching, because these cellular and molecular fallouts from these damaged leukemia cells and their normal counterparts in the blood circulation reach as far as any systemic organs. Such damage to normal cells and tissues might be long-term and probably permanently toxic [7, 58] . This is in-line with the rationale that the immune system not only responds to foreign substances (i.e. pathogens) but also responds to endogenously derived molecules that are expressed as a result of tissue damage or stressed cells, known as damage-associated molecular patterns (DAMPs) [59] , which can cause various diseases (e.g. autoimmune diseases) [60, 61] . Further, late onset of NT is another concern for cognitive dysfunction. Little is known about timing of the secondary and/or tertiary toxicities resulting from DAMPs. Referring to the pathogenesis and long-term course of many autoimmune diseases and neurocognitive disorders, a chronic, progressive disease process should be anticipated. Given the extreme importance to the young patient population uniquely targeted by Kymriah TM , it is worth knowing that classical genotoxicity assays and carcinogenicity assessment in vivo (rodent models) were not performed for Kymriah TM [7, 10] . Developmental and reproductive toxicity studies were not conducted in the nonclinical studies for Kymriah TM either [7, 10] . Thus, detection of long-term problems as such will not only be dependent on a longterm follow-up but also enhanced clinical awareness and sensitive detection algorithms are required for a goal-oriented evaluation. Taken together, the safety profiles and the toxic potential of Kymriah TM and Yescarta TM cannot be assessed in isolation for short-term monitoring and management but need to be considered together with a long-term follow-up. [58] . Media reports often state disproportionately on risk by overstating benefits while understating the harms [4, 58] . Nevertheless, the FDA plays a central part as an authoritative voice in communicating the benefits and risks of a drug [4] . It is important for all the stakeholders to become familiar with the FDA labels containing a Risk Evaluation and Mitigation Strategy (REMS) and an Elements to Assure Safe Use (ETASU) [1, 2, 7, 10] . Lifesaving care and preserving patient QOL are the tasks of modern medicine, being especially important for the patient populations of children and young adults. As more information about treatment options becomes available, patients, physicians, regulators and payers are reassessing how they balance the possible benefits and risks of therapeutic options [4] . Theoretically, no patients expect any treatment of procedure that is disproportionately costly, burdensome or painful [62] . However, practically, when doctors treat patients with life-threatening conditions (e.g. lethal cancers), the major focus would often be quickly directed toward instituting therapeutic measures to preserve life (lifesaving), and often they are unable to address the impact of medical care on QOL until after the lifesaving intervention [63] . Kymriah TM and Yescarta TM were regarded as a lifesaving treatment (a last-resort treatment) [1, 2] and fall within the scope of a formal debate in this regard. Ironically, where advances in technology and knowledge have given doctors an increased capacity to preserve and prolong life, some fundamental ethical questions could be raised in parallel: should doctors be concerned only with curing disease (lifesaving)? Do they have a responsibility to give the patients the best possible QOL while being physically or fiscally reasonable [63] ? These ethical dilemmas might have to be addressed at the clinic door that impacts individual patients by a participative management involving patients, doctors and other stakeholders. In this context, an ethical imperative requires classification of the medical significance of an intervention especially when the intervention remains controversial and underexamined, which will benefit from decreasing the uncertainty associated with the intervention.
Concluding remarks and future perspectives
Kymriah TM and Yescarta TM gained ground as last-resort treatments for R/R pediatric ALL and R/R adult B cell lymphoma, respectively, owing to their lifesaving potentials. The broad applications remain challenging because of acute lethal toxicities and also uncertain long-term impacts. Post-approval pharmacovigilance is crucial as one of the first considerations for risk mitigation of these known short-term toxicities. Long-term follow-up for durable efficacy and safety concerns is pending further progress. Furthermore, advances in manufacturing processes could reveal the better version of T-cellbased therapies, even beyond cancer therapy, to extrapolate the approach to treatment of infectious and autoimmune diseases. To this end, all efforts should be channeled into turning the ice bucket challenges into solutions and opportunities.
